ANVS Annovis Bio, Inc.

NYSE
$1.85

Annovis Bio, Inc. (ANVS) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.30 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.1% since its last earnings release on August 14, 2026.

Annovis Bio Beat Consensus Estimates
Friday, August 14, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · 7:30 AM ET
Earnings Whisper
-
vs ($0.30)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.88

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Annovis Bio, Inc.

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

Sector

Healthcare

Industry

Biotechnology